ARVO

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

Retrieved on: 
Tuesday, April 9, 2024
Research, NCP, KOL, ARVO, DED, Pain, FDA

LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.

Key Points: 
  • LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.
  • The Company is rescheduling its event so that it can incorporate additional key analyses of its clinical data which it plans to present at upcoming ophthalmic conferences.
  • OKYO is planning to make a presentation at “Dry Horizons Symposium Navigating the Future of Dry Eye Research”, an event preceding the Association for Research in Vision and Ophthalmology (ARVO) conference with details provided below.

Coave Therapeutics to Present at Upcoming Conferences

Retrieved on: 
Wednesday, March 27, 2024
Research, Congress, Gene, ARVO, Society, Cell

Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following upcoming investor and industry conferences:

Key Points: 
  • Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following upcoming investor and industry conferences:
    Cell & Gene Meeting on the Med – April 9-11 ; Rome, Italy
    LSX World Congress – April 29-30 ; London, UK
    BioEquity Europe – May 12-24 ; San Sebastián, Spain
    Gene Therapy Analytical Development Europe Summit - May 22-24 ; London, UK
    In addition, Coave’s scientific team will be present at the upcoming scientific, medical & regulatory conferences:
    ARVO (Association for Research in Vision and Ophthalmology) - May 5-6 ; Seattle, WA, US
    ASGCT (American Society of Gene and Cell Therapy) - May 7-11 ; Baltimore, MD, US

iHealthScreen Inc. is Awarded a US Patent on Glaucoma Detection, Which Is Based on AI and Color Fundus Imaging

Retrieved on: 
Tuesday, April 9, 2024
Physical Therapy, Technology, Managed Care, Health, Optical, Health Technology, Medical Devices, Photography, Software, Artificial Intelligence, Telemedicine, Virtual Medicine, Research, Diagnosis, Glaucoma, CE, Patient, Hospital, ARVO, IPredict, Paratriathlon, TGA, AMD, Diabetic retinopathy

The early screening and detection of glaucoma can potentially help prevent the progression to severe glaucoma and save millions of people from blindness.

Key Points: 
  • The early screening and detection of glaucoma can potentially help prevent the progression to severe glaucoma and save millions of people from blindness.
  • The entire test which includes color retinal imaging and the automated AI-based glaucoma report generation can easily and reliably be completed within 5 minutes.
  • Glaucoma detection offers an overall accuracy of 94.3% for identifying an individual with glaucoma.
  • iPredict’s glaucoma detection model can be used as follows:
    iPredict-glaucoma report will produce which will indicate referable (i.e., early to severe glaucoma) or non-referable glaucoma (not glaucoma).

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
ODD, Retina, Stargardt disease, Research, Conference, Vitamin A, Exercise, RPD, Eye, Patient, RBP4, Tissue, ARVO, ATM, Safety, Paratriathlon, Therapy, Macular degeneration, Blood, FDA, DRAGON, Food, Pharmaceutical industry

ET

Key Points: 
  • ET
    SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its audited financial results for full-year 2023 and the unaudited and unreviewed financial results for the quarter ended December 31, 2023, and provided a business update.
  • The decrease resulted primarily from higher R&D expenses in the fourth quarter of 2022 as the DRAGON trial reached certain milestones in such quarter.
  • Belite Bio will host a webcast on Tuesday, March 12, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.
  • A replay will be available for approximately 90 days following the event at the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events .

Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Research, CLD, Refractive surgery, ASCRS, Patient, Telecanthus, ARVO, University, Cataract, Abstract, Eyelid, Detail, Society, University of California, Irritation, Safety, MGD, Pain, Ophthalmic, Pharmaceutical industry

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).

Key Points: 
  • Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
  • This includes new, long-term data at ASCRS of the company’s lead drug candidate, AZR-MD-001, showing improvement in both signs and symptoms in MGD and Contact Lens Discomfort (CLD).
  • “Together, the data set we are presenting at these prestigious conferences show multiple potential patient benefits and mild, transient side effects in a topical medicine, supporting the potential of AZR-MD-001 as an entirely new approach targeting the underlying cause of many ocular surface diseases,” said Marc Gleeson, Chief Executive Officer of Azura.
  • This causes inflammatory ocular surface conditions, ocular surface dryness, pain, irritation, and reduced quality of vision.

Translational Vision Science and Technology Journal Publishes RadiusXR's NOVA Clinical Trial, Demonstrating Industry-Leading Accuracy and Innovation in Visual Field Testing for Virtual Reality Perimetry

Retrieved on: 
Monday, March 25, 2024
Wearables, Mobile Technology, Other Health, Seniors, Other Science, Pharmaceutical, Other Technology, Research, Optical, Software, Medical Devices, Hardware, Consumer, Science, Technology, Clinical Trials, General Health, Health, Health Technology, Diagnosis, Newton Aycliffe, Patient, ARVO, Digital health, Quality of life, Multimedia, Medicare, Clinical trial, Medical imaging

This milestone publication confirms RadiusXR's unwavering commitment to advancing ocular health and heralds a new era in visual field testing.

Key Points: 
  • This milestone publication confirms RadiusXR's unwavering commitment to advancing ocular health and heralds a new era in visual field testing.
  • Moreover, unlike other virtual reality perimeters (VRPs), RadiusXR measures vision within the photopic range, aligning with existing visual field platforms' standards.
  • "The publication of the NOVA Clinical Trial in TVST reaffirms RadiusXR's position as the leader in visual field testing innovation," remarked Ammad Khan, RadiusXR's Chief Executive Officer.
  • RadiusXR's innovative approach to visual field testing represents a significant advancement in the field of ophthalmology.

Voxeleron Appoints New CEO and Secures Funding to Continue Growing Its Innovative Ophthalmic Image Analysis Platform

Retrieved on: 
Wednesday, March 13, 2024
Other Health, Software, General Health, Professional Services, Data Management, Technology, Health Technology, Clinical Trials, Biotechnology, Finance, Other Technology, Health, Contract research organization, ICON, ARVO, Conference, Research, Lead, Growth, Ophthalmology

Voxeleron, a cloud-based ophthalmic image analysis platform provider, today announced the appointment of Joanna Williams as its new Chief Executive Officer (CEO).

Key Points: 
  • Voxeleron, a cloud-based ophthalmic image analysis platform provider, today announced the appointment of Joanna Williams as its new Chief Executive Officer (CEO).
  • She was most recently a Co-founder and Chief Operating Officer at Lexitas, a preeminent ophthalmology Contract Research Organization (CRO).
  • "We are at the forefront of the industry with innovative device-agnostic solutions that bring much-needed speed, accuracy, and versatility to ophthalmic clinical trials,” said Joanna Williams, CEO of Voxeleron.
  • Voxeleron will be showcasing its platform of AI-enabled ophthalmic image analysis tools at the upcoming ARVO 2024 Conference on May 5-9 in Seattle, Washington.

Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024

Retrieved on: 
Tuesday, April 2, 2024
Research, Biotechnology, Disease, Paratriathlon, Patient, Ageing, ARVO, Quality of life, Life expectancy, Retina, Bleeding, Pharmacokinetics, AMD, NAMD, Annual general meeting

Age-related macular degeneration (AMD) is a leading cause of severe vision loss and blindness for people aged 60 years and older in developed countries worldwide, with a profound impact on the quality of life of affected individuals.

Key Points: 
  • Age-related macular degeneration (AMD) is a leading cause of severe vision loss and blindness for people aged 60 years and older in developed countries worldwide, with a profound impact on the quality of life of affected individuals.
  • With the increase in life expectancy, the number of reported cases of AMD is increasing.
  • The disease and its current treatment regimen add significant burden on patients, caretakers, and on health care system.
  • nAMD accounts for roughly 10% of all AMD cases, but almost 90% of AMD-related central vision loss.

Avirmax Biopharma Inc. to Present at the 2024 ARVO Annual Meeting in Seattle

Retrieved on: 
Monday, April 1, 2024
Research, Neuroprotection, Sf9, Glaucoma, ARVO, HEK293, HEK 293 cells

HAYWARD, Calif., April 1, 2024 /PRNewswire/ -- Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.

Key Points: 
  • HAYWARD, Calif., April 1, 2024 /PRNewswire/ -- Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.
  • ARVO is the largest international society dedicated to ophthalmology and vision-related topics.
  • Dr. Shengjiang Liu, Ph.D. Chief Executive and Scientific Officer, is invited to present "Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells", at the 2024 ARVO Symposium on "Developing gene therapy for glaucoma neuroprotection: Opportunities and challenges", May 9, 8 – 10 am.
  • In addition to the invited talk, there will be two more scientific presentations from Avirmax Biopharma and an exhibitor booth #1604 to showcase the latest progress and data package:

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
Thursday, March 7, 2024
Therapy, ARVO, Research, Investment, FDA, Food, Sale, Șaeș, Exercise, Diabetic retinopathy, Safety, Visual acuity, AMD, Patient, Drug, Clinical trial, MOA, Net, Retina, Plasma, Conditional sentence, Angiogenesis, Pharmaceutical industry

ET –

Key Points: 
  • ET –
    WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and year ended December 31, 2023, and highlighted recent corporate developments.
  • “2023 was an exceptional year of execution and results for EyePoint Pharmaceuticals.
  • Review of Results for the Fourth Quarter Ended December 31, 2023
    For the quarter ended December 31, 2023, total net revenue was $14.0 million compared to $10.5 million for the quarter ended December 31, 2022.
  • ET to discuss the results for the fourth quarter and year ended December 31, 2023 and recent corporate developments.